Balakrishnan Karthik, Chen Yuanhong, Dong Jixin
Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Cancers (Basel). 2024 Aug 7;16(16):2783. doi: 10.3390/cancers16162783.
The objective of this study was to identify differentially expressed genes and their potential influence on the carcinogenesis of serous-type ovarian cancer tumors. Serous cancer is an epithelial ovarian cancer subtype and is the most common type of ovarian cancer. Transcriptomic profiles of serous cancer and non-cancerous datasets were obtained from the Gene Expression Omnibus (GEO-NCBI). Differentially expressed genes were then derived from those profiles; the identified genes were consistently upregulated in three or more transcriptomic profiles. These genes were considered as the serous ovarian cancer gene set for further study. The serous gene set derived from the transcriptomic profiles was then evaluated for ontological functional analysis using the Molecular Signatures Database. Next, we examined the mutational impact of this serous gene set on the transcriptomic profile of high-grade serous ovarian (HGSO) adenocarcinoma using the cBioPortal database. Results from OncoPrint revealed that 26 genes were amplified in more than 5% of HGSO cancer patients. Interestingly, several of these genes are involved in cell cycle processes, including genes ATPase family AAA domain containing 2 (ATAD2), recQ-like helicase 4 (RECQL4), cyclin E1 (CCNE1), anti-silencing function 1B histone chaperone (ASF1B), ribonuclease H2 subunit A (RNASEH2A), structural maintenance of chromosome 4 (SMC4), cell division cycle associated 20 (CDC20), and cell division cycle associated 8 (CDCA8). The receiver operating characteristic (ROC) curve results also revealed higher specificity and sensitivity for this subtype of tumors. Furthermore, these genes may affect the recurrence of serous ovarian carcinogenesis. Overall, our analytical study identifies cell cycle-related genes that can potentially be targeted as diagnostic and prognostic markers for serous ovarian cancer.
本研究的目的是鉴定差异表达基因及其对浆液性卵巢癌肿瘤发生的潜在影响。浆液性癌是上皮性卵巢癌的一种亚型，也是最常见的卵巢癌类型。浆液性癌和非癌数据集的转录组图谱来自基因表达综合数据库（GEO-NCBI）。然后从这些图谱中得出差异表达基因；所鉴定的基因在三个或更多转录组图谱中持续上调。这些基因被视为浆液性卵巢癌基因集以供进一步研究。然后使用分子特征数据库对从转录组图谱中得出的浆液性基因集进行本体功能分析。接下来，我们使用cBioPortal数据库检查了该浆液性基因集对高级别浆液性卵巢（HGSO）腺癌转录组图谱的突变影响。OncoPrint的结果显示，超过5%的HGSO癌症患者中有26个基因发生了扩增。有趣的是，其中几个基因参与细胞周期过程，包括含ATP酶家族AAA结构域2（ATAD2）、类recQ解旋酶4（RECQL）、细胞周期蛋白E1（CCNE1）、抗沉默功能1B组蛋白伴侣（ASF1B）、核糖核酸酶H2亚基A（RNASEH2A）、染色体结构维持蛋白4（SMC4）、细胞分裂周期相关蛋白20（CDC20）和细胞分裂周期相关蛋白8（CDCA8）。受试者工作特征（ROC）曲线结果还显示，该肿瘤亚型具有更高的特异性和敏感性。此外，这些基因可能影响浆液性卵巢癌发生的复发。总体而言，我们的分析研究确定了与细胞周期相关的基因，这些基因有可能作为浆液性卵巢癌的诊断和预后标志物。
